In recent years, the non-triglyceride lipotoxicity hypothesis, that free fatty acids and its metabolites are the real initiators/mediators of NASH, is being perceived as being more reflective of ...

Progressive chronic liver diseases, NASH and Primary Biliary Cholangitis (PBC), are a growing global epidemic with no or limited therapeutic option(s) and an addressable market size of over $35 ...

The investigational, liver-directed agent, designed to improve NASH by increasing hepatic fat metabolism and reducing lipotoxicity, was well-tolerated overall with a favorable safety profile.

To test the effects of SIRT6 on lipotoxicity, we analyzed the levels of SIRT6 in the hearts of diabetic mice and our results indicated an inverse correlation between SIRT6 and fatty acid transporters ...